Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 30
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The Findable, Accessible, Interoperable, Reusable (FAIR) Lite Principles to ensure utility of computational toxicology models

  • Cronin, Mark T. D.
  • March-Vila, Eric
  • Pastor Maeso, Manuel
  • Wedebye, Eva B.
A broad range of computational models is available for animal-free chemical safety assessment. The models are used to predict a variety of endpoints, including adverse effects or apical endpoints, toxicokinetic properties, and exposure, often from chemical structure or in vitro inputs alone. To support their wider use, such models need to be findable, accessible, interoperable, and reusable (FAIR). This study has reevaluated the existing FAIR principles applied to quantitative structure-activity relationships (QSARs) in order to adapt these principles to a wider range of computational models. Despite the breadth and variety of approaches, many computational models comprise common components including the training series, information about the modelling engine, and the model itself. As a result, a refined set of four FAIR Lite principles is proposed based on the methodological foundations of computational toxicology which are unambiguously understood by practitioners such as developers and end-users. To this end, it is proposed that to comply with the original FAIR principles, a computational toxicology model should be associated with (i) a globally unique identifier for model citation; (ii) the capture and curation of the model; (iii) the metadata for the dependent and independent variables and, where possible, data; and (iv) storage in a searchable and interoperable platform. The FAIR Lite principles are mapped onto the original FAIR principles applied to QSARs, thereby demonstrating that a simpler checklist approach covers all aspects. Plain language summary Many types of computational models are used in animal-free chemical safety assessment. These are used to make predictions for numerous endpoints, primarily focusing on the hazardous properties of, or exposure to, a chemical substance. The models use information from chemical structures and/or properties, or other non-animal data as inputs. It is essential that the risk assessor or toxicologist can find and utilize the models with confidence. The previously developed findable, accessible, interoperable and reusable (FAIR) principles for computational models are a framework intended to ensure that models are accessible and stored appropriately. This investigation has refined the original FAIR principles applied to computational models to capture information for all types of modelling approaches that may be used in chemical safety assessment. The new principles, termed FAIR Lite, encapsulate the original principles in four criteria relating to identifiers, description of a model, its (meta)data, and storage.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Usage of model combination in computational toxicology

  • Rodríguez-Belenguer, Pablo
  • March-Vila, Eric
  • Pastor Maeso, Manuel
  • Mangas Sanjuan, Victor
  • Soria Olivas, Emilio
New Approach Methodologies (NAMs) have ushered in a new era in the field of toxicology, aiming to replace animal testing. However, despite these advancements, they are not exempt from the inherent complexities associated with the study's endpoint. In this review, we have identified three major groups of complexities: mechanistic, chemical space, and methodological. The mechanistic complexity arises from interconnected biological processes within a network that are challenging to model in a single step. In the second group, chemical space complexity exhibits significant dissimilarity between compounds in the training and test series. The third group encompasses algorithmic and molecular descriptor limitations and typical class imbalance problems. To address these complexities, this work provides a guide to the usage of a combination of predictive Quantitative Structure-Activity Relationship (QSAR) models, known as metamodels. This combination of low-level models (LLMs) enables a more precise approach to the problem by focusing on different sub-mechanisms or sub-processes. For mechanistic complexity, multiple Molecular Initiating Events (MIEs) or levels of information are combined to form a mechanistic-based metamodel. Regarding the complexity arising from chemical space, two types of approaches were reviewed to construct a fragment-based chemical space metamodel: those with and without structure sharing. Metamodels with structure sharing utilize unsupervised strategies to identify data patterns and build low-level models for each cluster, which are then combined. For situations without structure sharing due to pharmaceutical industry intellectual property, the use of prediction sharing, and federated learning approaches have been reviewed. Lastly, to tackle methodological complexity, various algorithms are combined to overcome their limitations, diverse descriptors are employed to enhance problem definition and balanced dataset combinations are used to address class imbalance issues (methodological-based metamodels). Remarkably, metamodels consistently outperformed classical QSAR models across all cases, highlighting the importance of alternatives to classical QSAR models when faced with such complexities., The authors received funding from the European Union's Horizon 2020 Research and Innovation Programme under Grant Agreement No. 964537 (RISK-HUNT3R), which is part of the ASPIS cluster.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Identifying multiscale translational safety biomarkers using a network-based systems approach

  • Callegaro, Giulia
  • Schimming, Johannes P.
  • Piñero González, Janet, 1977-
  • Kunnen, Steven J.
  • Wijaya, Lukas
  • Trairatphisan, Panuwat
  • van den Berk, Linda
  • Beetsma, Kim
  • Furlong, Laura I.
  • Sutherland, Jeffrey J.
  • Mollon, Jennifer
  • Stevens, James L.
  • van de Water, Bob
Animal testing is the current standard for drug and chemicals safety assessment, but hazards translation to human is uncertain. Human in vitro models can address the species translation but might not replicate in vivo complexity. Herein, we propose a network-based method addressing these translational multiscale problems that derives in vivo liver injury biomarkers applicable to in vitro human early safety screening. We applied weighted correlation network analysis (WGCNA) to a large rat liver transcriptomic dataset to obtain co-regulated gene clusters (modules). We identified modules statistically associated with liver pathologies, including a module enriched for ATF4-regulated genes as associated with the occurrence of hepatocellular single-cell necrosis, and as preserved in human liver in vitro models. Within the module, we identified TRIB3 and MTHFD2 as a novel candidate stress biomarkers, and developed and used BAC-eGFPHepG2 reporters in a compound screening, identifying compounds showing ATF4-dependent stress response and potential early safety signals., This work was supported by the EU-EFPIA Innovative Medicines Initiative 2 (IMI2) Joint Undertaking TransQST project (grant number 116030) and eTRANSAFE project (grant number 777365) (this Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA), the EC Horizon2020 EU-ToxRisk project (grant number 681002), the European Research & Innovation project funded under the European Commission’s Horizon 2020 program RISK-HUNT3R project (grant number 964537) and the Cosmetics Europe/CEFIC Liver Ontology project.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Integrating mechanistic and toxicokinetic information in predictive models of cholestasis

  • Rodríguez-Belenguer, Pablo
  • Mangas Sanjuan, Victor
  • Soria Olivas, Emilio
  • Pastor Maeso, Manuel
Drug development involves the thorough assessment of the candidate's safety and efficacy. In silico toxicology (IST) methods can contribute to the assessment, complementing in vitro and in vivo experimental methods, since they have many advantages in terms of cost and time. Also, they are less demanding concerning the requirements of product and experimental animals. One of these methods, Quantitative Structure-Activity Relationships (QSAR), has been proven successful in predicting simple toxicity end points but has more difficulties in predicting end points involving more complex phenomena. We hypothesize that QSAR models can produce better predictions of these end points by combining multiple QSAR models describing simpler biological phenomena and incorporating pharmacokinetic (PK) information, using quantitative in vitro to in vivo extrapolation (QIVIVE) models. In this study, we applied our methodology to the prediction of cholestasis and compared it with direct QSAR models. Our results show a clear increase in sensitivity. The predictive quality of the models was further assessed to mimic realistic conditions where the query compounds show low similarity with the training series. Again, our methodology shows clear advantages over direct QSAR models in these situations. We conclude that the proposed methodology could improve existing methodologies and could be suitable for being applied to other toxicity end points., The authors received funding from the eTRANSAFE project, Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777365, European Union’s Horizon 2020, and EFPIA. The authors declare that this work reflects only the author’s view and that IMI-JU is not responsible for any use that may be made of the information it contains. Also, this project received funding from the European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement No. 964537 (RISK-HUNT3R), which is part of the ASPIS cluster.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Uncertainty assessment of proarrhythmia predictions derived from multi-level in silico models

  • Kopańska, Karolina
  • Rodríguez-Belenguer, Pablo
  • Llopis-Lorente, Jordi
  • Trenor, Beatriz
  • Saiz, Javier
  • Pastor Maeso, Manuel
In silico methods can be used for an early assessment of arrhythmogenic properties of drug candidates. However, their use for decision-making is conditioned by the possibility to estimate the predictions' uncertainty. This work describes our efforts to develop uncertainty quantification methods for the predictions produced by multi-level proarrhythmia models. In silico models used in this field usually start with experimental or predicted IC50 values that describe drug-induced ion channel blockade. Using such inputs, an electrophysiological model computes how the ion channel inhibition, exerted by a drug in a certain concentration, translates to an altered shape and duration of the action potential in cardiac cells, which can be represented as arrhythmogenic risk biomarkers such as the APD90. Using this framework, we identify the main sources of aleatory and epistemic uncertainties and propose a method based on probabilistic simulations that replaces single-point estimates predicted using multiple input values, including the IC50s and the electrophysiological parameters, by distributions of values. Two selected variability types associated with these inputs are then propagated through the multi-level model to estimate their impact on the uncertainty levels in the output, expressed by means of intervals. The proposed approach yields single predictions of arrhythmogenic risk biomarkers together with value intervals, providing a more comprehensive and realistic description of drug effects on a human population. The methodology was tested by predicting arrhythmogenic biomarkers on a series of twelve well-characterised marketed drugs, belonging to different arrhythmogenic risk classes., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. The authors received funding from the eTRANSAFE project, Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement No. 777365, supported from European Union’s Horizon 2020 and the EFPIA. Authors declare that this work reflects only the author’s view, and that IMI-JU is not responsible for any use that may be made of the information it contains. Also, this project received funding from the European Union’s Horizon 2020 Research and Innovation programme under Grant Agreement No. 964537 (RISK-HUNT3R), which is part of the ASPIS cluster. We also received funding from the SimCardioTest supported by European Union’s Horizon 2020 research and innovation programme under Grant Agreement No. 101016496. J.L.L. is being funded by the Ministerio de Ciencia, Innovacion y Universidades for the “Formacion de Profesorado Universitario” (Grant Reference: FPU18/01659). The work was also partially support by the Dirección General de Política Científica de la Generalitat Valenciana (PROMETEO/2020/043).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Making in silico predictive models for toxicology FAIR

  • Cronin, Mark T. D.
  • Belfield, Samuel J.
  • Briggs, Katharine
  • Enoch, Steven J.
  • Firman, James W.
  • Frericks, Markus
  • Garrard, Clare
  • Maccallum, Peter H.
  • Madden, Judith C.
  • Pastor Maeso, Manuel
  • Sanz, Ferran
  • Soininen, Inari
  • Sousoni, Despoina
In silico predictive models for toxicology include quantitative structure-activity relationship (QSAR) and physiologically based kinetic (PBK) approaches to predict physico-chemical and ADME properties, toxicological effects and internal exposure. Such models are used to fill data gaps as part of chemical risk assessment. There is a growing need to ensure in silico predictive models for toxicology are available for use and that they are reproducible. This paper describes how the FAIR (Findable, Accessible, Interoperable, Reusable) principles, developed for data sharing, have been applied to in silico predictive models. In particular, this investigation has focussed on how the FAIR principles could be applied to improved regulatory acceptance of predictions from such models. Eighteen principles have been developed that cover all aspects of FAIR. It is intended that FAIRification of in silico predictive models for toxicology will increase their use and acceptance., This research received funding from the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) under grant agreement eTRANSAFE (777365), the European Union’s Horizon 2020 ELIXIR-CONVERGE Project (871075) and research and innovation programme under grant agreement No 964537 (RISK-HUNT3R).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Moving towards making (quantitative) structure-activity relationships ((Q)SARs) for toxicity-related endpoints findable, accessible, interoperable and reusable (FAIR)

  • Belfield, Samuel J.
  • Basiri, Homa
  • Chavan, Swapnil
  • Chrysochoou, Georgios
  • Enoch, Steven J.
  • Firman, James W.
  • Gomatam, Anish
  • Hardy, Barry
  • Helmke, Palle S.
  • Madden, Judith C.
  • Maran, Uko
  • March-Vila, Eric
  • Nikolov, Nikolai G.
  • Pastor Maeso, Manuel
  • Piir, Geven
  • Sild, Sulev
  • Smajić, Aljoša
  • Spînu, Nicoleta
  • Wedebye, Eva B.
  • Cronin, Mark T. D.
(Quantitative) structure-activity relationships ((Q)SARs) are widely used in chemical safety assessment to predict toxicological effects. Many thousands of (Q)SAR models have been developed and published; however, few are easily available to use. This investigation has applied previously developed Findability, Accessibility, Interoperability, and Reuse (FAIR) Principles for in silico models to six published, different, machine learning (ML) (Q)SARs for the same toxicity dataset (inhibition of growth to Tetrahymena pyriformis). The majority of principles were met; however, there are still gaps in making (Q)SARs FAIR. This study has enabled insights into, and recommendations for, the FAIRification of (Q)SARs including areas where more work and effort may be required. For instance, there is still a need for (Q)SARs to be associated with a unique identifier and full data/metadata for toxicological activity or endpoints, molecular properties and descriptors, as well as model description to be provided in a standardized manner. A number of solutions to the challenges were identified, such as building on the QSAR Model Reporting Format (QMRF) and the application of QSAR Assessment Framework (QAF). This study also demonstrated that resources such as the QSAR Databank (QsarDB, www.qsardb.org) are valuable in storing ML QSARs in a searchable database and also provide a Digital Object Identifier (DOI). Many activities related to FAIR are currently underway and (Q)SAR modellers should be encouraged to utilise these to move towards the easier access and use of models. Enabling FAIR computational toxicology models will support the overall progress towards animal free chemical safety assessment., This project receives funding from the European Union's Horizon 2020 Research and Innovation programme under Grant Agreement No. 964537 (RISK-HUNT3R), and it is part of the ASPIS cluster; the Horizon Europe Framework Programme project Partnership for the Assessment of Risks from Chemicals (PARC, grant 101057014) under Task 5.2; and the QUANTUM-TOX - Revolutionizing Computational Toxicology with Electronic Structure Descriptors and Artificial Intelligence (QUANTUM-TOX) HORIZON-EIC-2023-PATHFINDEROPEN-01 Project number: 101130724. UM, SS, GP acknowledge support by the Ministry of Education and Research, Republic of Estonia, through Estonian Research Council (grant number PRG1509), Ministry of Climate, Republic of Estonia (grant 4-4/22/19), Ministry of Social Affairs, Republic of Estonia (grant 3-4/1593-1).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

An Alternative Safety Profiling Algorithm (ASPA) to transform next generation risk assessment into a structured and transparent process

  • Leist, Marcel
  • Pastor Maeso, Manuel
  • Luijten, Mirjam
Next generation risk assessment (NGRA) strategies use animal-free new approach methodologies (NAMs) to generate information concerning chemical hazard, toxicokinetics (ADME), and exposure. The information from these major pillars of data gathering is used to inform risk assessment and classification decisions. While the required types of data are widely agreed upon, the processes for data collection, integration and reporting, as well as several decisions on the depth and granularity of required data, are poorly standardized. Here, we present the Alternative Safety Profiling Algorithm (ASPA), a broad-purpose, transparent, and reproducible risk assessment workflow that allows documentation and integration of all types of information required for NGRA. ASPA aims to make safety assessments fully traceable for the recipient (e.g., a regulator), delineating which steps and decisions have led to the final outcome and why certain decisions were made. An overarching objective of ASPA is to ensure that identical data input yields identical outcomes in the hands of independent assessors. Therefore, ASPA is not just a data gathering workflow; it also considers data interdependencies and requires precise justification of intermediate decisions. This includes the monitoring and assessment of uncertainties. To assist users, the ASPA-assist software was developed. It formalizes the reporting process in a reproducible and standardized fashion. By guiding an operator step-by-step through the ASPA workflow, a complete and comprehensive report is assembled, whereby all data, methods, operator activities, and intermediate decisions are recorded. Practical examples illustrating the broader applicability of ASPA across various regulations and problem formulations are provided through case studies., This work has received funding from the European Union's Horizon 2020 research and innovation program under grant No. 964537 (RISK-HUNT3R), 963845 (ONTOX), and 965406 (PrecisionTox), which are all part of the ASPIS project cluster. Some authors have also been supported by PARC (The European Partnership for the Assessment of Risks from Chemicals). This project has received funding from the European Union's Horizon Europe research and innovation programme under Grant Agreement No. 101057014.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Genomic and proteomic biomarker landscape in clinical trials

  • Piñero González, Janet, 1977-
  • Rodriguez Fraga, Pablo S.
  • Valls-Margarit, Jordi
  • Ronzano, Francesco
  • Accuosto, Pablo
  • Lambea Jane, Ricard
  • Sanz, Ferran
  • Furlong, Laura I., 1971-
The use of molecular biomarkers to support disease diagnosis, monitor its progression, and guide drug treatment has gained traction in the last decades. While only a dozen biomarkers have been approved for their exploitation in the clinic by the FDA, many more are evaluated in the context of translational research and clinical trials. Furthermore, the information on which biomarkers are measured, for which purpose, and in relation to which conditions are not readily accessible: biomarkers used in clinical studies available through resources such as ClinicalTrials.gov are described as free text, posing significant challenges in finding, analyzing, and processing them by both humans and machines. We present a text mining strategy to identify proteomic and genomic biomarkers used in clinical trials and classify them according to the methodologies by which they are measured. We find more than 3000 biomarkers used in the context of 2600 diseases. By analyzing this dataset, we uncover patterns of use of biomarkers across therapeutic areas over time, including the biomarker type and their specificity. These data are made available at the Clinical Biomarker App at https://www.disgenet.org/biomarkers/, a new portal that enables the exploration of biomarkers extracted from the clinical studies available at ClinicalTrials.gov and enriched with information from the scientific literature. The App features several metrics that assess the specificity of the biomarkers, facilitating their selection and prioritization. Overall, the Clinical Biomarker App is a valuable and timely resource about clinical biomarkers, to accelerate biomarker discovery, development, and application., This work was partially funded by IMI2-JU grants, resources which are composed of financial contributions from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA [GA: 116030 TransQST and GA: 777365 eTRANSAFE], and the EU H2020 Programme [GA: 871075 Elixir-CONVERGE and GA:964537 RISKHUNT3R, which is part of the ASPIS cluster]; Project 001-P-001647—Valorisation of EGA for Industry and Society funded by the European Regional Development Fund (ERDF) and Generalitat de Catalunya; Agència de Gestió d’Ajuts Universitaris i de Recerca Generalitat de Catalunya [2017SGR00519], and the Institute of Health Carlos III (project IMPaCT-Data, exp. IMP/00019), co-funded by the European Union, European Regional Development Fund (ERDF, “A way to make Europe”). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and ERDF (PRB2-ISCIII [PT13/0001/0023, of the PE I + D + i 2013-2016]). The MELIS is a ‘Unidad de Excelencia María de Maeztu’, funded by the MINECO [MDM-2014-0370]. This work reflects only the author’s view and that the IMI2-JU is not responsible for any use that may be made of the information it contains. The European Commission is not responsible for any use that may be made of the information it contains.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A continuous in silico learning strategy to identify safety liabilities in compounds used in the leather and textile industry

  • March-Vila, Eric
  • Ferretti, Giacomo
  • Terricabras, Emma
  • Ardao, Inés
  • Brea, José Manuel
  • Varela, María José
  • Arana, Álvaro
  • Rubiolo, Juan Andrés
  • Sanz, Ferran
  • Loza, María I.
  • Sánchez, Laura
  • Alonso, Héctor
  • Pastor Maeso, Manuel
There is a widely recognized need to reduce human activity's impact on the environment. Many industries of the leather and textile sector (LTI), being aware of producing a significant amount of residues (Keßler et al. 2021; Liu et al. 2021), are adopting measures to reduce the impact of their processes on the environment, starting with a more comprehensive characterization of the chemical risk associated with the substances commonly used in LTI. The present work contributes to these efforts by compiling and toxicologically annotating the substances used in LTI, supporting a continuous learning strategy for characterizing their chemical safety. This strategy combines data collection from public sources, experimental methods and in silico predictions for characterizing four different endpoints: CMR, ED, PBT, and vPvB. We present the results of a prospective validation exercise in which we confirm that in silico methods can produce reasonably good hazard estimations and fill knowledge gaps in the LTI chemical space. The proposed protocol can speed the process and optimize the use of resources including the lives of experimental animals, contributing to identifying potentially harmful substances and their possible replacement by safer alternatives, thus reducing the environmental footprint and impact on human health.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Collaborative SAR modeling and prospective in vitro validation of oxidative stress activation in human HepG2 cells

  • Béquignon, Olivier J. M.
  • Gómez-Tamayo, José C.
  • Lenselink, Eelke B.
  • Wink, Steven
  • Hiemstra, Steven
  • Lam, Chi Chung
  • Gadaleta, Domenico
  • Roncaglioni, Alessandra
  • Norinder, Ulf
  • van de Water, Bob
  • Pastor Maeso, Manuel
  • van Westen, Gerard J. P.
Oxidative stress is the consequence of an abnormal increase of reactive oxygen species (ROS). ROS are generated mainly during the metabolism in both normal and pathological conditions as well as from exposure to xenobiotics. Xenobiotics can, on the one hand, disrupt molecular machinery involved in redox processes and, on the other hand, reduce the effectiveness of the antioxidant activity. Such dysregulation may lead to oxidative damage when combined with oxidative stress overpassing the cell capacity to detoxify ROS. In this work, a green fluorescent protein (GFP)-tagged nuclear factor erythroid 2-related factor 2 (NRF2)-regulated sulfiredoxin reporter (Srxn1-GFP) was used to measure the antioxidant response of HepG2 cells to a large series of drug and drug-like compounds (2230 compounds). These compounds were then classified as positive or negative depending on cellular response and distributed among different modeling groups to establish structure-activity relationship (SAR) models. A selection of models was used to prospectively predict oxidative stress induced by a new set of compounds subsequently experimentally tested to validate the model predictions. Altogether, this exercise exemplifies the different challenges of developing SAR models of a phenotypic cellular readout, model combination, chemical space selection, and results interpretation., This project received funding from the EU-ToxRisk and RISK-HUNT3R projects, which received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement Nos. 681002 and 964537, respectively, and was part of the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 777365 (eTRANSAFE) receiving support from the European Union’s Horizon 2020 research and innovation program and EFPIA. Additional funding was received from the VHP4Safety project, a research project funded by the Netherlands Research Council (NWO) “Netherlands Research Agenda: Research on Routes by Consortia” (NWA-ORC 1292.19.272). The authors declare that this work reflects only the author’s view and that the Innovative Medicines Initiative 2 Joint Undertaking and NWO are not responsible for any use that may be made of the information it contains.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

StreamChol: a web-based application for predicting cholestasis

  • Rodríguez-Belenguer, Pablo
  • Soria Olivas, Emilio
  • Pastor Maeso, Manuel
This article introduces StreamChol, a software for developing and applying mechanistic models to predict cholestasis. StreamChol is a Streamlit application, usable as a desktop application or web-accessible software when installed on a server using a docker container.StreamChol allows a seamless integration of pharmacokinetic analyses with Machine Learning models. This integration not only enables cholestasis prediction but also opens avenues for predicting other toxicological endpoints requiring similar integrations. StreamChol's Docker containerization also streamlines deployment across diverse environments, addressing potential compatibility issues. StreamChol is distributed as open-source under GNU GPL v3, reflecting our commitment to open science. Through StreamChol, researchers are offered a potent tool for predictive modelling in toxicology, harnessing its strengths within an intuitive and user-friendly interface, without the need for any programming knowledge.Scientific contribution This work offers a user-friendly web-based tool for cholestasis prediction and a complete workflow for creating web platforms that require the combination of both programming languages, R and Python., The authors received funding from the European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement No. 964537 (RISK-HUNT3R), which is part of the ASPIS cluster.
Repisalud
Publication Artículo científico (JournalArticle)

Trust your gut: Establishing confidence in gastrointestinal models - An overview of the state of the science and contexts of use.

  • Debad, Susan
  • Allen, David
  • Bandele, Omari
  • Bishop, Colin
  • Blaylock, Michaela
  • Brown, Paul
  • Bunger, Maureen K
  • Co, Julia Y
  • Crosby, Lynn
  • Daniel, Amber B
  • Ferguson, Steve S
  • Ford, Kevin
  • Gamboa da Costa, Gonçalo
  • Gilchrist, Kristin H
  • Grogg, Matthew W
  • Gwinn, Maureen
  • Hartung, Thomas
  • Hogan, Simon P
  • Jeong, Ye Eun
  • Kass, George EN
  • Kenyon, Elaina
  • Kleinstreuer, Nicole C
  • Kujala, Ville
  • Lundquist, Patrik
  • Matheson, Joanna
  • McCullough, Shaun D
  • Melton-Celsa, Angela
  • Musser, Steven
  • Oh, Ilung
  • Oyetade, Oluwakemi B
  • Patil, Sarita U
  • Petersen, Elijah J
  • Sadrieh, Nakissa
  • Sayes, Christie M
  • Scruggs, Benjamin S
  • Tan, Yu-Mei
  • Thelin, Bill
  • Nelson, M Tyler
  • Tarazona, Jose
  • Wambaugh, John F
  • Yang, Jun-Young
  • Yu, Changwoo
  • Fitzpatrick, Suzanne
The webinar series and workshop titled “Trust Your Gut: Establishing Confidence in Gastrointestinal Models – An Overview of the State of the Science and Contexts of Use” was co-organized by NICEATM, NIEHS, FDA, EPA, CPSC, DoD, and the Johns Hopkins Center for Alternatives to Animal Testing (CAAT) and hosted at the National Institutes of Health in Bethesda, MD, USA on October 11-12, 2023. New approach methods (NAMs) for assessing issues of gastrointestinal tract (GIT)- related toxicity offer promise in addressing some of the limitations associated with animal-based assessments. GIT NAMs vary in complexity, from two-dimensional monolayer cell line-based systems to sophisticated 3-dimensional organoid systems derived from human primary cells. Despite advances in GIT NAMs, challenges remain in fully replicating the complex interactions and pro­cesses occurring within the human GIT. Presentations and discussions addressed regulatory needs, challenges, and innovations in incorporating NAMs into risk assessment frameworks; explored the state of the science in using NAMs for evaluating systemic toxicity, understanding absorption and pharmacokinetics, evaluating GIT toxicity, and assessing potential allergenicity; and discussed strengths, limitations, and data gaps of GIT NAMs as well as steps needed to establish confidence in these models for use in the regulatory setting. Plain language summary: Non-animal methods to assess whether chemicals may be toxic to the human digestive tract promise to complement or improve on animal-based methods. These approaches, which are based on human or animal cells and/or computer models, are faced with their own technical challenges and need to be shown to predict adverse effects in humans. Regulators are tasked with evaluating submitted data to best protect human health and the environment. A webinar series and workshop brought together scientists from academia, industry, military, and regulatory authorities from dif­ferent countries to discuss how non-animal methods can be integrated into the risk assessment of drugs, food additives, dietary supplements, pesticides, and industrial chemicals for gastrointestinal toxicity.
Repisalud
Publication Artículo científico (JournalArticle)

New approach methods to assess developmental and adult neurotoxicity for regulatory use: a PARC work package 5 project

  • Tal, Tamara
  • Myhre, Oddvar
  • Fritsche, Ellen
  • Rüegg, Joëlle
  • Craenen, Kai
  • Aiello-Holden, Kiara
  • Agrillo, Caroline
  • Babin, Patrick J
  • Escher, Beate I
  • Dirven, Hubert
  • Hellsten, Kati
  • Dolva, Kristine
  • Hessel, Ellen
  • Heusinkveld, Harm J
  • Hadzhiev, Yavor
  • Hurem, Selma
  • Jagiello, Karolina
  • Judzinska, Beata
  • Klüver, Nils
  • Knoll-Gellida, Anja
  • Kühne, Britta A
  • Leist, Marcel
  • Lislien, Malene
  • Lyche, Jan L
  • Müller, Ferenc
  • Colbourne, John K
  • Neuhaus, Winfried
  • Pallocca, Giorgia
  • Seeger, Bettina
  • Scharkin, Ilka
  • Scholz, Stefan
  • Spjuth, Ola
  • Torres-Ruiz, Mónica
  • Bartmann, Kristina
In the European regulatory context, rodent in vivo studies are the predominant source of neurotoxicity information. Although they form a cornerstone of neurotoxicological assessments, they are costly and the topic of ethical debate. While the public expects chemicals and products to be safe for the developing and mature nervous systems, considerable numbers of chemicals in commerce have not, or only to a limited extent, been assessed for their potential to cause neurotoxicity. As such, there is a societal push toward the replacement of animal models with in vitro or alternative methods. New approach methods (NAMs) can contribute to the regulatory knowledge base, increase chemical safety, and modernize chemical hazard and risk assessment. Provided they reach an acceptable level of regulatory relevance and reliability, NAMs may be considered as replacements for specific in vivo studies. The European Partnership for the Assessment of Risks from Chemicals (PARC) addresses challenges to the development and implementation of NAMs in chemical risk assessment. In collaboration with regulatory agencies, Project 5.2.1e (Neurotoxicity) aims to develop and evaluate NAMs for developmental neurotoxicity (DNT) and adult neurotoxicity (ANT) and to understand the applicability domain of specific NAMs for the detection of endocrine disruption and epigenetic perturbation. To speed up assay time and reduce costs, we identify early indicators of later-onset effects. Ultimately, we will assemble second-generation developmental neurotoxicity and first-generation adult neurotoxicity test batteries, both of which aim to provide regulatory hazard and risk assessors and industry stakeholders with robust, speedy, lower-cost, and informative next-generation hazard and risk assessment tools.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Uncertainty assessment of proarrhythmia predictions derived from multi-level in silico models

  • Kopanska, Karolina
  • Rodriguez-Belenguer, Pablo
  • Llopis-Lorente, Jordi
  • Pastor, Manuel
  • Trenor Gomis, Beatriz Ana|||0000-0001-9166-6112
  • Saiz Rodríguez, Francisco Javier|||0000-0002-9850-0825
[EN] In silico methods can be used for an early assessment of arrhythmogenic properties of drug candidates. However, their use for decision-making is conditioned by the possibility to estimate the predictions' uncertainty. This work describes our efforts to develop uncertainty quantification methods for the predictions produced by multi-level proarrhythmia models. In silico models used in this field usually start with experimental or predicted IC50 values that describe drug-induced ion channel blockade. Using such inputs, an electrophysiological model computes how the ion channel inhibition, exerted by a drug in a certain concentration, translates to an altered shape and duration of the action potential in cardiac cells, which can be represented as arrhythmogenic risk biomarkers such as the APD(90). Using this framework, we identify the main sources of aleatory and epistemic uncertainties and propose a method based on probabilistic simulations that replaces single-point estimates predicted using multiple input values, including the IC(50)s and the electrophysiological parameters, by distributions of values. Two selected variability types associated with these inputs are then propagated through the multi-level model to estimate their impact on the uncertainty levels in the output, expressed by means of intervals. The proposed approach yields single predictions of arrhythmogenic risk biomarkers together with value intervals, providing a more comprehensive and realistic description of drug effects on a human population. The methodology was tested by predicting arrhythmogenic biomarkers on a series of twelve well-characterised marketed drugs, belonging to different arrhythmogenic risk classes., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. The authors received funding from the eTRANSAFE project, Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement No. 777365, supported from European Union s Horizon 2020 and the EFPIA. Authors declare that this work refects only the author s view, and that IMI-JU is not responsible for any use that may be made of the information it contains. Also, this project received funding from the European Union s Horizon 2020 Research and Innovation programme under Grant Agreement No. 964537 (RISK-HUNT3R), which is part of the ASPIS cluster. We also received funding from the SimCardioTest supported by European Union s Horizon 2020 research and innovation programme under Grant Agreement No. 101016496. J.L.L. is being funded by the Ministerio de Ciencia, Innovacion y Universidades for the Formacion de Profesorado Universitario (Grant Reference: FPU18/01659). The work was also partially support by the Dirección General de Política Científca de la Generalitat Valenciana (PROMETEO/2020/043).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Tesis doctoral (DoctoralThesis)

Computational Approaches for Next-Generation Risk Assessment of Hepatic Toxicity

  • Ortega Vallbona, Rita Carmen
[ES] El daño hepático inducido por fármacos, o DILI (del inglés Drug-Induced Liver Injury), entendido también como el daño hepático causado por la exposición a otros xenobióticos, es una causa frecuente de retirada de fármacos en desarrollo. Las manifestaciones clínicas del DILI van desde el daño hepatocelular o colestático hasta la esteatosis y la fibrosis. Aunque suele resolverse tras la interrupción del tratamiento, el DILI puede progresar a insuficiencia hepática aguda, que puede resultar mortal. La complejidad de las vías biológicas implicadas en el DILI dificulta enormemente su predicción. En la evaluación de riesgos de nueva generación, enfoques relevantes para el ser humano aportan información sobre los mecanismos de toxicidad. Idealmente, estos mecanismos se compilan en redes AOP (del inglés Adverse Outcome Pathway) que conectan los MIEs (del inglés Molecular Initiating Events) y los KEs (del inglés Key Events) con un efecto adverso. En esta tesis se exploran métodos computacionales para incorporar predicciones en una red AOP y reforzar la evidencia durante su desarrollo y transición a una AOP cuantitativa. En el primer capítulo, revisamos ejemplos de enfoques in silico que se han utilizado para abordar diferentes componentes en el AOP de esteatosis, incluyendo modelos (Q)SAR (del inglés (Quantitative) Structure-Avtivity Relationships), read-across, análisis ómicos y métodos basados en modelado molecular. En el segundo capítulo, desarrollamos modelos (Q)SAR para dos tipos de acumulación de lípidos inducida por sustancias químicas, tomando un grupo reducido de ácidos carboxílicos que presentan diferentes efectos en células HepG2 con sólo pequeñas variaciones en su estructura química. En el tercer capítulo, aplicamos modelado molecular para predecir la alteración de MIEs tras la exposición a compuestos. Presentamos un servidor de acoplamiento molecular automatizado, con proteínas preparadas, que permiten simular la unión de un compuesto con una lista de proteínas de interés, ofreciendo la energía de unión y un análisis de las interacciones proteína-ligando, que podría mejorar la clasificación del compuesto introducido como potencial ligando. Este trabajo pretende tender un puente hacia la aplicación de estos métodos computacionales para la evaluación de riesgos de próxima generación, destacando la importancia de la información mecanística y la transparencia de las herramientas, para favorecer su aceptación regulatoria en protocolos informados por AOPs., [CA] El dany hepàtic induït per fàrmacs, o DILI (de l'anglés Drug-Induced Liver Injury), entés també com el dany hepàtic causat per l'exposició altres xenobiòtics, és una causa freqüent de retirada de fàrmacs en desenvolupament. Les manifestacions clíniques del DILI van des del dany hepatocel·lular o colestàtic fins a l'esteatosi o fibrosi. Encara sol resoldre's en interrompre el tractament, el DILI pot progressar a insuficiència hepàtica aguda, que pot resultar mortal. La complexitat de les vies metabòliques implicades en el DILI dificulta enormement la seua predicció. En l'avaluació de riscos de nova generació, enfocaments rellevants per a l'ésser humà oferixen informació sobre els mecanismes de toxicitat. Idealment, estos mecanismes es compilen en xarxes AOP (de l'anglés Adverse Outcome Pathway) que connecten els MIEs (de l'anglés Molecular Initiating Events) i els KEs (de l'anglés Key Events) amb un efecte advers. En esta tesi s'exploren mètodes computacionals per a incorporar prediccions en una xarxa AOP i reforçar l'evidència durant el seu desenvolupament i transició a una AOP quantitativa. En el primer capítol, revisem exemples d'aproximacions in silico que s'han utilitzat per a abordar diferents components en l'AOP d'esteatosi, que inclouen models (Q)SAR (de l'anglés (Quantitative) Structure-Avtivity Relationships), read-across, anàlisis òmics i mètodes basats en modelatge molecular. En el segon capítol, desenvolupem models (Q)SAR per a dos tipus d'acumulació de lípids induïda per substàncies químiques, prenent un grup reduït d'àcids carboxílics que presenten diferents efectes en cèl·lules HepG2 amb només xicotetes variacions en la seua estructura química. En el tercer capítol, apliquem modelat molecular per a predir l'alteració de MIEs per exposició a compostos. Presentem un servidor d'acoblament molecular automatitzat, amb proteïnes preparades, que permeten simular la unió d'un compost amb una llista de proteïnes d'interés, oferint l'energia d'unió i una anàlisi de les interaccions proteïna-lligand, que podria millorar la classificació del compost introduït com a potencial lligand. Este treball pretén bastir un pont cap a l'aplicació d'estos mètodes computacionals per a l'avaluació de riscos de pròxima generació, destacant la importància de la informació mecanística i la transparència de les ferramentes, per a afavorir l'acceptació reguladora d'estes metodologies per al seu ús en protocols informats per AOPs., [EN] Drug-induced liver injury (DILI), understood as liver damage caused by exposure to drugs or other xenobiotics, is one of the main reasons for drug attrition. The clinical manifestations of DILI range from hepatocellular and cholestatic damage to steatosis and fibrosis. While most cases of DILI resolve after discontinuation, it can progress to life-threatening conditions, such as acute liver failure. The network of biological pathways that can lead to the appearance of DILI is very complex and involves numerous mechanisms, making the prediction of DILI extremely difficult. In the context of next-generation risk assessment, the use of human-relevant approaches offers insights into the mechanisms of toxicity. The knowledge about these mechanisms is ideally gathered into Adverse Outcome Pathway (AOP) networks that connect Molecular Initiating Events (MIEs) and Key Events (KEs) to an adverse outcome. In this thesis, we explore several computational methodologies that can be used to input data predictions into an AOP network to add to the weight of evidence during its development and transition to a quantitative AOP. In the first chapter, we review examples of in silico approaches that have been used to address different building blocks in the steatosis AOP, including (Quantitative) Structure-Activity Relationships ((Q)SAR) models, read-across, omics analysis, and structure-based methods. In the second chapter, we develop (Q)SAR models for two types of chemical-induced lipid accumulation, taking a small group of carboxylic acids that present different effects in HepG2 cells with only small variations in their chemical structure. In the third chapter, we switch to the use of structure-based methods for the prediction of MIE alteration by exposure to compounds. We explain how we have developed an automated docking server with prepared protein structures that allow for the binding of query compounds to the set of proteins of interest and not only offer the binding energy as a result but also analyse the protein-ligand interactions and use that to add information that could lead to a better classification of the query compounds as binders or non-binders. Overall, the work presented here intends to bridge the application of computational approaches for next-generation risk assessment. By emphasizing the importance of mechanistic information and tool transparency, this work aims to aid in advancing the regulatory acceptance of these approaches to be used in AOP-informed hazard assessment pipelines., This work was performed as part of the ASPIS cluster (https://aspis-cluster.eu/), funded by the European Union’s Horizon 2020 Research and Innovation Programme under grant agreements No 963845 (ONTOX, https://ontox-project.eu/), No 965406 (PrecisionTox, https://precisiontox.org/), and No 964537 (RISK-HUNT3R, https://www.risk-hunt3r.eu/). This work also received support from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No 681002 (EU-ToxRisk) and from CIBERHED (Spain). In addition, this work was funded by Instituto de Salud Carlos III (ISCIII), co-funded by the European Union, through grant PI21/00223. We gratefully acknowledge the financial support of the Agencia Valenciana de la Investigación (AVI, https://innoavi.es/en/) through its Innodocto programme (reference numbers INNTA3/2022/13 and INNTA3/2021/14), financed by the European Union through the European Regional Development Fund (ERDF) programme 2021–2027 Comunitat Valenciana. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 872195 (MSCA-RISE “VIDEC”). The Swedish Research Council (Vetenskapsrådet) and the Swedish Cancer Foundation are gratefully acknowledged for funding (LAE). Allocation of supercomputing time at C3SE (Gothenburg) and NSC (Linköping) was provided by the National Academic Infrastructure for Supercomputing in Sweden (NAISS), partially funded by the Swedish Research Council through grant agreement No 2022-06725.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publication Artículo científico (JournalArticle)

A continuous in silico learning strategy to identify safety liabilities in compounds used in the leather and textile industry

  • March-Vila, Eric
  • Ferretti, Giacomo
  • Terricabras, Emma
  • Ardao Palacios, Inés
  • Brea Floriani, José Manuel
  • Varela, María José
  • Arana Díaz, Álvaro Jesús
  • Rubiolo Gaytán, Juan Andrés
  • Sanz, Ferran
  • Loza García, María Isabel
  • Sánchez Piñón, Laura
  • Alonso, Héctor
  • Pastor, Manuel
There is a widely recognized need to reduce human activity's impact on the environment. Many industries of the leather and textile sector (LTI), being aware of producing a significant amount of residues (Keßler et al. 2021; Liu et al. 2021), are adopting measures to reduce the impact of their processes on the environment, starting with a more comprehensive characterization of the chemical risk associated with the substances commonly used in LTI. The present work contributes to these efforts by compiling and toxicologically annotating the substances used in LTI, supporting a continuous learning strategy for characterizing their chemical safety. This strategy combines data collection from public sources, experimental methods and in silico predictions for characterizing four different endpoints: CMR, ED, PBT, and vPvB. We present the results of a prospective validation exercise in which we confirm that in silico methods can produce reasonably good hazard estimations and fill knowledge gaps in the LTI chemical space. The proposed protocol can speed the process and optimize the use of resources including the lives of experimental animals, contributing to identifying potentially harmful substances and their possible replacement by safer alternatives, thus reducing the environmental footprint and impact on human health.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Drug-target identification in COVID-19 disease mechanisms using computational systems biology approaches

  • Niarakis, Anna
  • Ostaszewski, Marek
  • Mazein, Alexander
  • Kuperstein, Inna
  • Kutmon, Martina
  • Gillespie, Marc E.
  • Funahashi, Akira
  • Acencio, Marcio Luis
  • Hemedan, Ahmed
  • Aichem, Michael
  • Klein, Karsten
  • Czauderna, Tobias
  • Burtscher, Felicia
  • Yamada, Takahiro G.
  • Hiki, Yusuke
  • Hiroi, Noriko F.
  • Hu, Finterly
  • Pham, Nhung
  • Ehrhart, Friederike
  • Willighagen, Egon L.
  • Valdeolivas, Alberto
  • Dugourd, Aurelien
  • Messina, Francesco
  • Esteban-Medina, Marina
  • Peña-Chilet, María
  • Rian, Kinza
  • Soliman, Sylvain
  • Aghamiri, Sara Sadat
  • Lal Puniya, Bhanwar
  • Naldi, Aurelien
  • Helikar, Tomas
  • Singh, Vidisha
  • Fariñas Fernández, Marco
  • Bermudez, Viviam
  • Tsirvouli, Eirini
  • Montagud, Arnau
  • Noël, Vincent
  • Ponce de León, Miguel
  • Maier, Dieter
  • Bauch, Angela
  • Gyori, Benjamin M.
  • Bachman, John A.
  • Luna, Augustin
  • Piñero, Janet
  • Furlong, Laura I.
  • Balaur, Irina BalaurIrina
  • Rougny, Adrien
  • Jarosz, Yohan
  • Overall, Rupert W.
  • Phair, Robert
  • Perfetto, Livia
  • Matthews, Lisa
  • Balaya Rex, Devasahayam Arokia
  • Orlic-Milacic, Marija
  • Monraz Gómez, Luis Cristóbal
  • De Meulder, Bertrand
  • Ravel, Jean-Marie
  • Jassal, Bijay
  • Satagopam, Venkata
  • Wu, Guanming
  • Golebiewski, Martin
  • Gawron, Piotr
  • Calzone, Laurence
  • Beckmann, Jacques S.
  • Evelo, Chris T.
  • D’Eustachio, Peter
  • Schreiber, Falk
  • Sáez-Rodríguez, Julio
  • Dopazo, Joaquín
  • Kuiper, Martin
  • Valencia, Alfonso
  • Wolkenhauer, Olaf
  • Kitano, Hiroaki
  • Barillot, Emmanuel
  • Auffray, Charles
  • Balling, Rudi
  • Schneider, Reinhard
  • COVID- Disease Map Community the COVID-19 Disease Map Community
© 2024 Niarakis, Ostaszewski, Mazein, Kuperstein, Kutmon, Gillespie, Funahashi, Acencio, Hemedan, Aichem, Klein, Czauderna, Burtscher, Yamada, Hiki, Hiroi, Hu, Pham, Ehrhart, Willighagen, Valdeolivas, Dugourd, Messina, Esteban-Medina, Peña-Chilet, Rian, Soliman, Aghamiri, Puniya, Naldi, Helikar, Singh, Fernández, Bermudez, Tsirvouli, Montagud, Noël, Ponce-de-Leon, Maier, Bauch, Gyori, Bachman, Luna, Piñero, Furlong, Balaur, Rougny, Jarosz, Overall, Phair, Perfetto, Matthews, Rex, Orlic-Milacic, Gomez, De Meulder, Ravel, Jassal, Satagopam, Wu, Golebiewski, Gawron, Calzone, Beckmann, Evelo, D’Eustachio, Schreiber, Saez-Rodriguez, Dopazo, Kuiper, Valencia, Wolkenhauer, Kitano, Barillot, Auffray, Balling, Schneider and the COVID-19 Disease Map Community. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms., Introduction: The COVID-19 Disease Map project is a large-scale community effort uniting 277 scientists from 130 Institutions around the globe. We use high-quality, mechanistic content describing SARS-CoV-2-host interactions and develop interoperable bioinformatic pipelines for novel target identification and drug repurposing., Methods: Extensive community work allowed an impressive step forward in building interfaces between Systems Biology tools and platforms. Our framework can link biomolecules from omics data analysis and computational modelling to dysregulated pathways in a cell-, tissue- or patient-specific manner. Drug repurposing using text mining and AI-assisted analysis identified potential drugs, chemicals and microRNAs that could target the identified key factors., Results: Results revealed drugs already tested for anti-COVID-19 efficacy, providing a mechanistic context for their mode of action, and drugs already in clinical trials for treating other diseases, never tested against COVID-19., Discussion: The key advance is that the proposed framework is versatile and expandable, offering a significant upgrade in the arsenal for virus-host interactions and other complex pathologies., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. AN acknowledges support from SANOFI-AVENTIS R&D via the CIFRE contract, n° 2020/0766. MK, FH, NP, FE, and CE acknowledge the support of the ZonMw COVID-19 programme (Grant No. 10430012010015). JD Spanish Ministry of Science and Innovation (Grant no. PID2020-117979RB-I00) and Instituto de Salud Carlos III (Grant no. IMP/00019). MAi, KK, FS: Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) - Project-ID 251654672 - TRR 161 and under Germany’s Excellence Strategy - EXC 2117 - 422037984. FM: “5 per 1000–2021” grant of the Italian Ministry of Health (Grant No. 5M-2021-23683787) and European Commission with HORIZON programme, BY-COVID project (Grant No. 101046203—BY-COVID). National Institute for Infectious Diseases Lazzaro Spallanzani–IRCCS received financial support from the Italian Ministry of Health grant “Ricerca Corrente”. JP, LF: IMI2-JU grants, resources which are composed of financial contributions from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA [GA: 777365 eTRANSAFE], and the EU H2020 Programme [GA:964537 RISKHUNT3R]; Project 001-P-001647—Valorisation of EGA for Industry and Society funded by the European Regional Development Fund (ERDF) and Generalitat de Catalunya; Institute of Health Carlos III (project IMPaCT-Data, exp. IMP/00019), co-funded by the European Union, European Regional Development Fund (ERDF, “A way to make Europe”). AMo, MP and AV acknowledge the support of the European Commission under the INFORE project (H2020-ICT-825070) and the PerMedCoE (H2020-ICT-951773). Contributions by TH and BLP were supported by NIH grant #R35GM119770 to TH. MaGo acknowledges funding from Deutsche Forschungsgemeinschaft (DFG) through grants no. 442326535 (NFDI4Health) and 451265285 (NFDI4Health Task Force COVID-19), from the European Commission through the Horizon 2020 framework program under grant no. 825843 (EU-STANDS4PM) and through the Digital Europe program under grant no. 101083771 (EDITH), as well as from the Klaus Tschira Foundation. AL acknowledges support from the Intramural Research Program of the National Library of Medicine (NLM), National Institutes of Health (NIH)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Integrating mechanistic and toxicokinetic information in predictive models of cholestasis

  • Rodríguez-Belenguer, Pablo
  • Mangas Sanjuan, Victor
  • Soria Olivas, Emilio
  • Pastor Maeso, Manuel
Drug development involves the thorough assessment of the candidate's safety and efficacy. In silico toxicology (IST) methods can contribute to the assessment, complementing in vitro and in vivo experimental methods, since they have many advantages in terms of cost and time. Also, they are less demanding concerning the requirements of product and experimental animals. One of these methods, Quantitative Structure-Activity Relationships (QSAR), has been proven successful in predicting simple toxicity end points but has more difficulties in predicting end points involving more complex phenomena. We hypothesize that QSAR models can produce better predictions of these end points by combining multiple QSAR models describing simpler biological phenomena and incorporating pharmacokinetic (PK) information, using quantitative in vitro to in vivo extrapolation (QIVIVE) models. In this study, we applied our methodology to the prediction of cholestasis and compared it with direct QSAR models. Our results show a clear increase in sensitivity. The predictive quality of the models was further assessed to mimic realistic conditions where the query compounds show low similarity with the training series. Again, our methodology shows clear advantages over direct QSAR models in these situations. We conclude that the proposed methodology could improve existing methodologies and could be suitable for being applied to other toxicity end points., The authors received funding from the eTRANSAFE project, Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777365, European Union’s Horizon 2020, and EFPIA. The authors declare that this work reflects only the author’s view and that IMI-JU is not responsible for any use that may be made of the information it contains. Also, this project received funding from the European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement No. 964537 (RISK-HUNT3R), which is part of the ASPIS cluster.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Uncertainty assessment of proarrhythmia predictions derived from multi-level in silico models

  • Kopańska, Karolina
  • Rodríguez-Belenguer, Pablo
  • Llopis-Lorente, Jordi
  • Trenor, Beatriz
  • Saiz, Javier
  • Pastor Maeso, Manuel
In silico methods can be used for an early assessment of arrhythmogenic properties of drug candidates. However, their use for decision-making is conditioned by the possibility to estimate the predictions' uncertainty. This work describes our efforts to develop uncertainty quantification methods for the predictions produced by multi-level proarrhythmia models. In silico models used in this field usually start with experimental or predicted IC50 values that describe drug-induced ion channel blockade. Using such inputs, an electrophysiological model computes how the ion channel inhibition, exerted by a drug in a certain concentration, translates to an altered shape and duration of the action potential in cardiac cells, which can be represented as arrhythmogenic risk biomarkers such as the APD90. Using this framework, we identify the main sources of aleatory and epistemic uncertainties and propose a method based on probabilistic simulations that replaces single-point estimates predicted using multiple input values, including the IC50s and the electrophysiological parameters, by distributions of values. Two selected variability types associated with these inputs are then propagated through the multi-level model to estimate their impact on the uncertainty levels in the output, expressed by means of intervals. The proposed approach yields single predictions of arrhythmogenic risk biomarkers together with value intervals, providing a more comprehensive and realistic description of drug effects on a human population. The methodology was tested by predicting arrhythmogenic biomarkers on a series of twelve well-characterised marketed drugs, belonging to different arrhythmogenic risk classes., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. The authors received funding from the eTRANSAFE project, Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement No. 777365, supported from European Union’s Horizon 2020 and the EFPIA. Authors declare that this work reflects only the author’s view, and that IMI-JU is not responsible for any use that may be made of the information it contains. Also, this project received funding from the European Union’s Horizon 2020 Research and Innovation programme under Grant Agreement No. 964537 (RISK-HUNT3R), which is part of the ASPIS cluster. We also received funding from the SimCardioTest supported by European Union’s Horizon 2020 research and innovation programme under Grant Agreement No. 101016496. J.L.L. is being funded by the Ministerio de Ciencia, Innovacion y Universidades for the “Formacion de Profesorado Universitario” (Grant Reference: FPU18/01659). The work was also partially support by the Dirección General de Política Científica de la Generalitat Valenciana (PROMETEO/2020/043).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Collaborative SAR modeling and prospective in vitro validation of oxidative stress activation in human HepG2 cells

  • Béquignon, Olivier J. M.
  • Gómez-Tamayo, José C.
  • Lenselink, Eelke B.
  • Wink, Steven
  • Hiemstra, Steven
  • Lam, Chi Chung
  • Gadaleta, Domenico
  • Roncaglioni, Alessandra
  • Norinder, Ulf
  • van de Water, Bob
  • Pastor Maeso, Manuel
  • van Westen, Gerard J. P.
Oxidative stress is the consequence of an abnormal increase of reactive oxygen species (ROS). ROS are generated mainly during the metabolism in both normal and pathological conditions as well as from exposure to xenobiotics. Xenobiotics can, on the one hand, disrupt molecular machinery involved in redox processes and, on the other hand, reduce the effectiveness of the antioxidant activity. Such dysregulation may lead to oxidative damage when combined with oxidative stress overpassing the cell capacity to detoxify ROS. In this work, a green fluorescent protein (GFP)-tagged nuclear factor erythroid 2-related factor 2 (NRF2)-regulated sulfiredoxin reporter (Srxn1-GFP) was used to measure the antioxidant response of HepG2 cells to a large series of drug and drug-like compounds (2230 compounds). These compounds were then classified as positive or negative depending on cellular response and distributed among different modeling groups to establish structure-activity relationship (SAR) models. A selection of models was used to prospectively predict oxidative stress induced by a new set of compounds subsequently experimentally tested to validate the model predictions. Altogether, this exercise exemplifies the different challenges of developing SAR models of a phenotypic cellular readout, model combination, chemical space selection, and results interpretation., This project received funding from the EU-ToxRisk and RISK-HUNT3R projects, which received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement Nos. 681002 and 964537, respectively, and was part of the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 777365 (eTRANSAFE) receiving support from the European Union’s Horizon 2020 research and innovation program and EFPIA. Additional funding was received from the VHP4Safety project, a research project funded by the Netherlands Research Council (NWO) “Netherlands Research Agenda: Research on Routes by Consortia” (NWA-ORC 1292.19.272). The authors declare that this work reflects only the author’s view and that the Innovative Medicines Initiative 2 Joint Undertaking and NWO are not responsible for any use that may be made of the information it contains.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A continuous in silico learning strategy to identify safety liabilities in compounds used in the leather and textile industry

  • March-Vila, Eric
  • Ferretti, Giacomo
  • Terricabras, Emma
  • Ardao, Inés
  • Brea, José Manuel
  • Varela, María José
  • Arana, Álvaro
  • Rubiolo, Juan Andrés
  • Sanz, Ferran
  • Loza, María I.
  • Sánchez, Laura
  • Alonso, Héctor
  • Pastor Maeso, Manuel
There is a widely recognized need to reduce human activity's impact on the environment. Many industries of the leather and textile sector (LTI), being aware of producing a significant amount of residues (Keßler et al. 2021; Liu et al. 2021), are adopting measures to reduce the impact of their processes on the environment, starting with a more comprehensive characterization of the chemical risk associated with the substances commonly used in LTI. The present work contributes to these efforts by compiling and toxicologically annotating the substances used in LTI, supporting a continuous learning strategy for characterizing their chemical safety. This strategy combines data collection from public sources, experimental methods and in silico predictions for characterizing four different endpoints: CMR, ED, PBT, and vPvB. We present the results of a prospective validation exercise in which we confirm that in silico methods can produce reasonably good hazard estimations and fill knowledge gaps in the LTI chemical space. The proposed protocol can speed the process and optimize the use of resources including the lives of experimental animals, contributing to identifying potentially harmful substances and their possible replacement by safer alternatives, thus reducing the environmental footprint and impact on human health.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

An Alternative Safety Profiling Algorithm (ASPA) to transform next generation risk assessment into a structured and transparent process

  • Leist, Marcel
  • Pastor Maeso, Manuel
  • Luijten, Mirjam
Next generation risk assessment (NGRA) strategies use animal-free new approach methodologies (NAMs) to generate information concerning chemical hazard, toxicokinetics (ADME), and exposure. The information from these major pillars of data gathering is used to inform risk assessment and classification decisions. While the required types of data are widely agreed upon, the processes for data collection, integration and reporting, as well as several decisions on the depth and granularity of required data, are poorly standardized. Here, we present the Alternative Safety Profiling Algorithm (ASPA), a broad-purpose, transparent, and reproducible risk assessment workflow that allows documentation and integration of all types of information required for NGRA. ASPA aims to make safety assessments fully traceable for the recipient (e.g., a regulator), delineating which steps and decisions have led to the final outcome and why certain decisions were made. An overarching objective of ASPA is to ensure that identical data input yields identical outcomes in the hands of independent assessors. Therefore, ASPA is not just a data gathering workflow; it also considers data interdependencies and requires precise justification of intermediate decisions. This includes the monitoring and assessment of uncertainties. To assist users, the ASPA-assist software was developed. It formalizes the reporting process in a reproducible and standardized fashion. By guiding an operator step-by-step through the ASPA workflow, a complete and comprehensive report is assembled, whereby all data, methods, operator activities, and intermediate decisions are recorded. Practical examples illustrating the broader applicability of ASPA across various regulations and problem formulations are provided through case studies., This work has received funding from the European Union's Horizon 2020 research and innovation program under grant No. 964537 (RISK-HUNT3R), 963845 (ONTOX), and 965406 (PrecisionTox), which are all part of the ASPIS project cluster. Some authors have also been supported by PARC (The European Partnership for the Assessment of Risks from Chemicals). This project has received funding from the European Union's Horizon Europe research and innovation programme under Grant Agreement No. 101057014.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Identifying multiscale translational safety biomarkers using a network-based systems approach

  • Callegaro, Giulia
  • Schimming, Johannes P.
  • Piñero González, Janet, 1977-
  • Kunnen, Steven J.
  • Wijaya, Lukas
  • Trairatphisan, Panuwat
  • van den Berk, Linda
  • Beetsma, Kim
  • Furlong, Laura I.
  • Sutherland, Jeffrey J.
  • Mollon, Jennifer
  • Stevens, James L.
  • van de Water, Bob
Animal testing is the current standard for drug and chemicals safety assessment, but hazards translation to human is uncertain. Human in vitro models can address the species translation but might not replicate in vivo complexity. Herein, we propose a network-based method addressing these translational multiscale problems that derives in vivo liver injury biomarkers applicable to in vitro human early safety screening. We applied weighted correlation network analysis (WGCNA) to a large rat liver transcriptomic dataset to obtain co-regulated gene clusters (modules). We identified modules statistically associated with liver pathologies, including a module enriched for ATF4-regulated genes as associated with the occurrence of hepatocellular single-cell necrosis, and as preserved in human liver in vitro models. Within the module, we identified TRIB3 and MTHFD2 as a novel candidate stress biomarkers, and developed and used BAC-eGFPHepG2 reporters in a compound screening, identifying compounds showing ATF4-dependent stress response and potential early safety signals., This work was supported by the EU-EFPIA Innovative Medicines Initiative 2 (IMI2) Joint Undertaking TransQST project (grant number 116030) and eTRANSAFE project (grant number 777365) (this Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA), the EC Horizon2020 EU-ToxRisk project (grant number 681002), the European Research & Innovation project funded under the European Commission’s Horizon 2020 program RISK-HUNT3R project (grant number 964537) and the Cosmetics Europe/CEFIC Liver Ontology project.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Moving towards making (quantitative) structure-activity relationships ((Q)SARs) for toxicity-related endpoints findable, accessible, interoperable and reusable (FAIR)

  • Belfield, Samuel J.
  • Basiri, Homa
  • Chavan, Swapnil
  • Chrysochoou, Georgios
  • Enoch, Steven J.
  • Firman, James W.
  • Gomatam, Anish
  • Hardy, Barry
  • Helmke, Palle S.
  • Madden, Judith C.
  • Maran, Uko
  • March-Vila, Eric
  • Nikolov, Nikolai G.
  • Pastor Maeso, Manuel
  • Piir, Geven
  • Sild, Sulev
  • Smajić, Aljoša
  • Spînu, Nicoleta
  • Wedebye, Eva B.
  • Cronin, Mark T. D.
(Quantitative) structure-activity relationships ((Q)SARs) are widely used in chemical safety assessment to predict toxicological effects. Many thousands of (Q)SAR models have been developed and published; however, few are easily available to use. This investigation has applied previously developed Findability, Accessibility, Interoperability, and Reuse (FAIR) Principles for in silico models to six published, different, machine learning (ML) (Q)SARs for the same toxicity dataset (inhibition of growth to Tetrahymena pyriformis). The majority of principles were met; however, there are still gaps in making (Q)SARs FAIR. This study has enabled insights into, and recommendations for, the FAIRification of (Q)SARs including areas where more work and effort may be required. For instance, there is still a need for (Q)SARs to be associated with a unique identifier and full data/metadata for toxicological activity or endpoints, molecular properties and descriptors, as well as model description to be provided in a standardized manner. A number of solutions to the challenges were identified, such as building on the QSAR Model Reporting Format (QMRF) and the application of QSAR Assessment Framework (QAF). This study also demonstrated that resources such as the QSAR Databank (QsarDB, www.qsardb.org) are valuable in storing ML QSARs in a searchable database and also provide a Digital Object Identifier (DOI). Many activities related to FAIR are currently underway and (Q)SAR modellers should be encouraged to utilise these to move towards the easier access and use of models. Enabling FAIR computational toxicology models will support the overall progress towards animal free chemical safety assessment., This project receives funding from the European Union's Horizon 2020 Research and Innovation programme under Grant Agreement No. 964537 (RISK-HUNT3R), and it is part of the ASPIS cluster; the Horizon Europe Framework Programme project Partnership for the Assessment of Risks from Chemicals (PARC, grant 101057014) under Task 5.2; and the QUANTUM-TOX - Revolutionizing Computational Toxicology with Electronic Structure Descriptors and Artificial Intelligence (QUANTUM-TOX) HORIZON-EIC-2023-PATHFINDEROPEN-01 Project number: 101130724. UM, SS, GP acknowledge support by the Ministry of Education and Research, Republic of Estonia, through Estonian Research Council (grant number PRG1509), Ministry of Climate, Republic of Estonia (grant 4-4/22/19), Ministry of Social Affairs, Republic of Estonia (grant 3-4/1593-1).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Usage of model combination in computational toxicology

  • Rodríguez-Belenguer, Pablo
  • March-Vila, Eric
  • Pastor Maeso, Manuel
  • Mangas Sanjuan, Victor
  • Soria Olivas, Emilio
New Approach Methodologies (NAMs) have ushered in a new era in the field of toxicology, aiming to replace animal testing. However, despite these advancements, they are not exempt from the inherent complexities associated with the study's endpoint. In this review, we have identified three major groups of complexities: mechanistic, chemical space, and methodological. The mechanistic complexity arises from interconnected biological processes within a network that are challenging to model in a single step. In the second group, chemical space complexity exhibits significant dissimilarity between compounds in the training and test series. The third group encompasses algorithmic and molecular descriptor limitations and typical class imbalance problems. To address these complexities, this work provides a guide to the usage of a combination of predictive Quantitative Structure-Activity Relationship (QSAR) models, known as metamodels. This combination of low-level models (LLMs) enables a more precise approach to the problem by focusing on different sub-mechanisms or sub-processes. For mechanistic complexity, multiple Molecular Initiating Events (MIEs) or levels of information are combined to form a mechanistic-based metamodel. Regarding the complexity arising from chemical space, two types of approaches were reviewed to construct a fragment-based chemical space metamodel: those with and without structure sharing. Metamodels with structure sharing utilize unsupervised strategies to identify data patterns and build low-level models for each cluster, which are then combined. For situations without structure sharing due to pharmaceutical industry intellectual property, the use of prediction sharing, and federated learning approaches have been reviewed. Lastly, to tackle methodological complexity, various algorithms are combined to overcome their limitations, diverse descriptors are employed to enhance problem definition and balanced dataset combinations are used to address class imbalance issues (methodological-based metamodels). Remarkably, metamodels consistently outperformed classical QSAR models across all cases, highlighting the importance of alternatives to classical QSAR models when faced with such complexities., The authors received funding from the European Union's Horizon 2020 Research and Innovation Programme under Grant Agreement No. 964537 (RISK-HUNT3R), which is part of the ASPIS cluster.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Making in silico predictive models for toxicology FAIR

  • Cronin, Mark T. D.
  • Belfield, Samuel J.
  • Briggs, Katharine
  • Enoch, Steven J.
  • Firman, James W.
  • Frericks, Markus
  • Garrard, Clare
  • Maccallum, Peter H.
  • Madden, Judith C.
  • Pastor Maeso, Manuel
  • Sanz, Ferran
  • Soininen, Inari
  • Sousoni, Despoina
In silico predictive models for toxicology include quantitative structure-activity relationship (QSAR) and physiologically based kinetic (PBK) approaches to predict physico-chemical and ADME properties, toxicological effects and internal exposure. Such models are used to fill data gaps as part of chemical risk assessment. There is a growing need to ensure in silico predictive models for toxicology are available for use and that they are reproducible. This paper describes how the FAIR (Findable, Accessible, Interoperable, Reusable) principles, developed for data sharing, have been applied to in silico predictive models. In particular, this investigation has focussed on how the FAIR principles could be applied to improved regulatory acceptance of predictions from such models. Eighteen principles have been developed that cover all aspects of FAIR. It is intended that FAIRification of in silico predictive models for toxicology will increase their use and acceptance., This research received funding from the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) under grant agreement eTRANSAFE (777365), the European Union’s Horizon 2020 ELIXIR-CONVERGE Project (871075) and research and innovation programme under grant agreement No 964537 (RISK-HUNT3R).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

StreamChol: a web-based application for predicting cholestasis

  • Rodríguez-Belenguer, Pablo
  • Soria Olivas, Emilio
  • Pastor Maeso, Manuel
This article introduces StreamChol, a software for developing and applying mechanistic models to predict cholestasis. StreamChol is a Streamlit application, usable as a desktop application or web-accessible software when installed on a server using a docker container.StreamChol allows a seamless integration of pharmacokinetic analyses with Machine Learning models. This integration not only enables cholestasis prediction but also opens avenues for predicting other toxicological endpoints requiring similar integrations. StreamChol's Docker containerization also streamlines deployment across diverse environments, addressing potential compatibility issues. StreamChol is distributed as open-source under GNU GPL v3, reflecting our commitment to open science. Through StreamChol, researchers are offered a potent tool for predictive modelling in toxicology, harnessing its strengths within an intuitive and user-friendly interface, without the need for any programming knowledge.Scientific contribution This work offers a user-friendly web-based tool for cholestasis prediction and a complete workflow for creating web platforms that require the combination of both programming languages, R and Python., The authors received funding from the European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement No. 964537 (RISK-HUNT3R), which is part of the ASPIS cluster.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The Findable, Accessible, Interoperable, Reusable (FAIR) Lite Principles to ensure utility of computational toxicology models

  • Cronin, Mark T. D.
  • March-Vila, Eric
  • Pastor Maeso, Manuel
  • Wedebye, Eva B.
A broad range of computational models is available for animal-free chemical safety assessment. The models are used to predict a variety of endpoints, including adverse effects or apical endpoints, toxicokinetic properties, and exposure, often from chemical structure or in vitro inputs alone. To support their wider use, such models need to be findable, accessible, interoperable, and reusable (FAIR). This study has reevaluated the existing FAIR principles applied to quantitative structure-activity relationships (QSARs) in order to adapt these principles to a wider range of computational models. Despite the breadth and variety of approaches, many computational models comprise common components including the training series, information about the modelling engine, and the model itself. As a result, a refined set of four FAIR Lite principles is proposed based on the methodological foundations of computational toxicology which are unambiguously understood by practitioners such as developers and end-users. To this end, it is proposed that to comply with the original FAIR principles, a computational toxicology model should be associated with (i) a globally unique identifier for model citation; (ii) the capture and curation of the model; (iii) the metadata for the dependent and independent variables and, where possible, data; and (iv) storage in a searchable and interoperable platform. The FAIR Lite principles are mapped onto the original FAIR principles applied to QSARs, thereby demonstrating that a simpler checklist approach covers all aspects. Plain language summary Many types of computational models are used in animal-free chemical safety assessment. These are used to make predictions for numerous endpoints, primarily focusing on the hazardous properties of, or exposure to, a chemical substance. The models use information from chemical structures and/or properties, or other non-animal data as inputs. It is essential that the risk assessor or toxicologist can find and utilize the models with confidence. The previously developed findable, accessible, interoperable and reusable (FAIR) principles for computational models are a framework intended to ensure that models are accessible and stored appropriately. This investigation has refined the original FAIR principles applied to computational models to capture information for all types of modelling approaches that may be used in chemical safety assessment. The new principles, termed FAIR Lite, encapsulate the original principles in four criteria relating to identifiers, description of a model, its (meta)data, and storage.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Genomic and proteomic biomarker landscape in clinical trials

  • Piñero González, Janet, 1977-
  • Rodriguez Fraga, Pablo S.
  • Valls-Margarit, Jordi
  • Ronzano, Francesco
  • Accuosto, Pablo
  • Lambea Jane, Ricard
  • Sanz, Ferran
  • Furlong, Laura I., 1971-
The use of molecular biomarkers to support disease diagnosis, monitor its progression, and guide drug treatment has gained traction in the last decades. While only a dozen biomarkers have been approved for their exploitation in the clinic by the FDA, many more are evaluated in the context of translational research and clinical trials. Furthermore, the information on which biomarkers are measured, for which purpose, and in relation to which conditions are not readily accessible: biomarkers used in clinical studies available through resources such as ClinicalTrials.gov are described as free text, posing significant challenges in finding, analyzing, and processing them by both humans and machines. We present a text mining strategy to identify proteomic and genomic biomarkers used in clinical trials and classify them according to the methodologies by which they are measured. We find more than 3000 biomarkers used in the context of 2600 diseases. By analyzing this dataset, we uncover patterns of use of biomarkers across therapeutic areas over time, including the biomarker type and their specificity. These data are made available at the Clinical Biomarker App at https://www.disgenet.org/biomarkers/, a new portal that enables the exploration of biomarkers extracted from the clinical studies available at ClinicalTrials.gov and enriched with information from the scientific literature. The App features several metrics that assess the specificity of the biomarkers, facilitating their selection and prioritization. Overall, the Clinical Biomarker App is a valuable and timely resource about clinical biomarkers, to accelerate biomarker discovery, development, and application., This work was partially funded by IMI2-JU grants, resources which are composed of financial contributions from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA [GA: 116030 TransQST and GA: 777365 eTRANSAFE], and the EU H2020 Programme [GA: 871075 Elixir-CONVERGE and GA:964537 RISKHUNT3R, which is part of the ASPIS cluster]; Project 001-P-001647—Valorisation of EGA for Industry and Society funded by the European Regional Development Fund (ERDF) and Generalitat de Catalunya; Agència de Gestió d’Ajuts Universitaris i de Recerca Generalitat de Catalunya [2017SGR00519], and the Institute of Health Carlos III (project IMPaCT-Data, exp. IMP/00019), co-funded by the European Union, European Regional Development Fund (ERDF, “A way to make Europe”). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and ERDF (PRB2-ISCIII [PT13/0001/0023, of the PE I + D + i 2013-2016]). The MELIS is a ‘Unidad de Excelencia María de Maeztu’, funded by the MINECO [MDM-2014-0370]. This work reflects only the author’s view and that the IMI2-JU is not responsible for any use that may be made of the information it contains. The European Commission is not responsible for any use that may be made of the information it contains.